US stock · Healthcare sector · Biotechnology
Company Logo

Arena Pharmaceuticals, Inc.

ARNANASDAQ

99.99

USD
- -
(- -)
Pre Market
-9.96P/E
-13Forward P/E
-0.38P/E to S&P500
6.165BMarket CAP
- -Div Yield
Upcoming Earnings
3 Aug-8 Aug
Shares Short
2/28/22
6.02M
Short % of Float
11.32%
Short % of Shares Outs.
9.77%
% Held by Insiders
0.27%
% Held by Institutions
83.86%
Beta
0.55
PEG Ratio
0.58
52w. high/low
100.00/45.50
Avg. Daily Volume
1.47M
Return %
Stock
S&P 500
1 year
46.01
(1.30)
3 years
122.45
40.60
5 years
629.85
72.91
Scale: |
High
Low
147.80
77.60
86.80
27.00
74.20
22.60
80.00
12.60
26.20
12.10
135.00
15.10
110.00
40.50
79.70
32.60
62.80
16.00
21.60
13.00
35.09
11.30
50.05
30.00
64.48
38.18
90.19
32.95
94.08
45.53
100.00
89.05
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
Revenue per share
6.54
3.08
1.33
1.23
1.52
0.91
1.40
3.73
1.68
1.59
5.10
0.65
0.38
16.20
0.01
0.00
Earnings per share
(18.45)
(22.80)
(32.17)
(18.16)
(11.37)
(7.85)
(4.35)
(0.89)
(2.75)
(4.49)
(0.93)
(2.77)
(0.62)
7.99
(7.39)
(11.26)
FCF per share
(18.23)
(23.19)
(31.72)
(19.12)
(5.16)
(5.67)
(2.33)
2.92
(5.02)
(4.53)
(2.59)
(2.02)
(2.83)
11.33
(6.46)
(9.55)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
3.04
2.78
5.79
0.63
0.38
0.04
0.09
0.42
0.41
0.46
0.04
0.00
0.01
0.10
0.01
1.30
Book Value per sh.
78.31
53.58
15.93
8.84
7.30
0.76
5.02
4.21
2.15
2.22
1.64
6.28
12.89
21.52
19.73
12.29
Comm.Shares outs.
5
6
7
8
11
14
20
22
22
24
24
33
47
50
55
55
Avg. annual P/E ratio
(7.6)
(5.2)
(1.8)
(2.3)
(3.0)
(2.0)
(14.7)
(81.2)
(19.7)
(8.0)
(17.9)
(7.3)
(64.1)
6.3
(8.2)
(5.9)
P/E to S&P500
(0.4)
(0.3)
(0.1)
(0.0)
(0.1)
(0.1)
(1.0)
(4.8)
(1.1)
(0.4)
(0.8)
(0.3)
(2.6)
0.3
(0.2)
(0.2)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
31
19
10
10
17
13
28
81
37
38
124
21
18
806
0
0
Operating margin
(303.6)%
(818.8)%
(2,405.2)%
(1,332.3)%
(580.0)%
(651.0)%
(207.0)%
(28.2)%
(284.8)%
(269.3)%
(13.8)%
(431.0)%
(805.7)%
59.9%
(133,742.6)%
(1,156,109.3)%
Depreciation (m)
8
9
15
15
13
11
10
8
9
10
9
4
4
3
4
4
Net profit (m)
(86)
(143)
(238)
(153)
(125)
(109)
(85)
(19)
(61)
(108)
(23)
(91)
(29)
398
(405)
(616)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
79.4%
21.7%
- -
- -
Net profit margin
(282.1)%
(740.6)%
(2,422.0)%
(1,475.0)%
(749.6)%
(858.7)%
(309.8)%
(23.9)%
(163.7)%
(281.7)%
(18.2)%
(428.4)%
(163.6)%
49.3%
(126,875.9)%
(1,141,542.6)%
Working capital (m)
364
379
70
101
120
46
141
178
115
125
56
209
431
715
1,081
503
Long-term debt (m)
- -
- -
- -
57
27
15
- -
- -
- -
- -
- -
- -
- -
- -
- -
36
Equity (m)
366
336
118
75
80
11
99
92
47
54
40
207
606
1,071
1,080
673
ROIC
- -
- -
- -
- -
- -
- -
(33.0)%
(4.6)%
(25.6)%
(48.9)%
(15.3)%
(31.9)%
(4.2)%
35.5%
(35.3)%
(85.2)%
Return on capital
(18.0)%
(29.4)%
(98.4)%
(56.9)%
(38.6)%
(60.4)%
(29.2)%
(3.6)%
(19.4)%
(39.4)%
(9.5)%
(25.1)%
(19.5)%
43.7%
(33.6)%
(78.0)%
Return on equity
(23.6)%
(42.6)%
(202.0)%
(205.5)%
(155.6)%
(1,034.1)%
(86.7)%
(21.2)%
(127.8)%
(201.7)%
(56.4)%
(44.1)%
(4.8)%
37.1%
(37.5)%
(91.6)%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
(2.3)%
- -
- -
Capital Structure
23 Feb · 2022 | Q4
All numbers in millions
Total liabilities
$ 111
Total assets
$ 785
Long-term debt
$ 36
Cash and equiv.
$ 225
Goodwill
$ - -
Retained earnings
$ (2,124)
Common stock
61
Enterprise Value
$ 5,977
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
740
1,104
550
Receivables
2
- -
- -
Inventory
- -
- -
- -
Other
19
12
0
Current assets
760
1,139
569
Acc. Payable
6
12
13
Debt due
4
4
5
Other
35
42
48
Current liabilities
45
58
66
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(83.07)%
1,047.21%
497.07%
Cash flow
47.78%
(135.04)%
(121.09)%
Earnings
52.31%
(417.40)%
(136.70)%
Dividends
- -
- -
- -
Book value
(37.69)%
58.14%
64.88%
Insider Trading
Type
Shares
Date
Neil Garry Arthur
Return
7,202
03/11/22
Neil Garry Arthur
Other
3,067
03/11/22
Neil Garry Arthur
Other
8,150
03/11/22
Jarrett Jennifer
Return
7,202
03/11/22
Jarrett Jennifer
Other
3,067
03/11/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2019
801
1
1
3
806
2020
0
- -
0
0
0
2021
- -
- -
- -
0
0
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2019
12.46
(1.23)
(1.46)
(1.77)
7.99
2020
(1.83)
(1.55)
(1.78)
(2.23)
(7.39)
2021
(2.16)
(2.67)
(3.58)
(2.84)
(11.26)
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2019
- -
- -
- -
- -
- -
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Biotechnology
CEO:
Mr. Amit Munshi
Full-time employees:
448
City:
San Diego
Address:
6154 Nancy Ridge Dr
IPO:
Jul 28, 2000
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.